Physician profile
Eugene T Conte
NPI 1316056567
$226,287.85
in general payments reported to CMS, 2019-2025
25 companies · $424 in 2025
The $424 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162K · 2020: $24K · 2021: $11K · 2022: $29K · 2023: $630 · 2024: $510 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039 · Travel and Lodging: $282 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.48 |
| Travel and Lodging | $282.26 |
| Education | $242.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $72,078.41 | 2019-2025 | Ebglyss |
| Celgene Corporation | $46,312.96 | 2019 | |
| Amgen INC. | $41,436.44 | 2020-2023 | Otezla |
| Abbvie INC. | $40,883.30 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $20,351.29 | 2019-2025 | |
| Pfizer INC. | $3,555.88 | 2019 | |
| Janssen Biotech, INC. | $558.91 | 2019-2024 | Tremfya |
| Genzyme Corporation | $283.24 | 2021-2025 | |
| Ucb, INC. | $150.34 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $138.24 | 2025 | Zoryve |
| Dermira, INC. | $97.02 | 2019 | |
| Sun Pharmaceutical Industries INC. | $79.81 | 2019-2022 | |
| Leo Pharma INC. | $53.56 | 2019-2023 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.42 | 2021 | |
| Almirall LLC | $41.41 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $36.04 | 2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $35.31 | 2020-2021 | |
| Vyne Pharmaceuticals INC. | $26.29 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.15 | 2025 | Sotyktu |
| Medimetriks Pharmaceuticals, INC. | $19.43 | 2025 | |
| Hill Dermaceuticals, INC. | $17.46 | 2021 | |
| Dusa Pharmaceuticals, INC. | $16.95 | 2019 | |
| Incyte Corporation | $15.77 | 2025 | Opzelura |
| Mayne Pharma Commercial LLC | $14.53 | 2019 | |
| Encore Dermatology INC. | $12.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Conte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.